Latest Philadelphia chromosome Stories
NEW YORK, Dec. 6, 2010 /PRNewswire/ -- Pfizer Inc.
EAST HANOVER, N.J., Dec.
NEW YORK, Dec. 3, 2010 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) announced today it is planning regulatory submissions of bosutinib in patients with chronic myeloid leukemia (CML) based on data from a clinical program evaluating the compound in newly diagnosed and previously treated patients.
Whitehead Institute researchers have shown in mouse models that overexpression of the microRNA 125b (miR-125b) can independently cause leukemia and accelerate the disease's progression.
Patients with rare type of leukemia now have another treatment option SILVER SPRING, Md., Oct. 28 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a new indication for Sprycel (dasatinib) for the treatment of a rare blood cancer when it is first diagnosed.
SUNNYVALE, Calif., Oct.
PHILADELPHIA, Aug. 25 /PRNewswire/ -- In celebration of a seminal discovery in cancer biology, Fox Chase Cancer Center will host the Philadelphia Chromosome Symposium: Past, Present and Future, on September 28, 2010, from 8 a.m. to 7 p.m.
WHITE PLAINS, N.Y., July 26 /PRNewswire/ -- Kareem Abdul-Jabbar, basketball legend and the NBA's all-time leading scorer, is asking his supporters to join him in taking a shot at beating cancer by joining his team - Team Kareem. In 2009, after Kareem's diagnosis with Philadelphia chromosome-positive chronic myeloid leukemia, (Ph+ CML), a slow progressing type of blood cancer(1), he initiated a CML education program with Novartis Oncology to show people that they are not alone in fighting this...
EAST HANOVER, N.J., June 17 /PRNewswire/ -- Following a priority review, the US Food and Drug Administration (FDA) has approved TasignaÂ® (nilotinib) 150 mg capsules for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Approval expands use in treatment of rare type of leukemia SILVER SPRING, Md., June 17 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a new indication for Tasigna (nilotinib) for the treatment of a rare blood cancer when it is first diagnosed.